These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23136211)

  • 1. Control of mineral metabolism and bone disease in haemodialysis patients: which optimal targets?
    Fouque D; Roth H; Pelletier S; London GM; Hannedouche T; Jean G; Bouchet JL; Drüeke T
    Nephrol Dial Transplant; 2013 Feb; 28(2):360-7. PubMed ID: 23136211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
    Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
    J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
    Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients.
    Taniguchi M; Fukagawa M; Fujii N; Hamano T; Shoji T; Yokoyama K; Nakai S; Shigematsu T; Iseki K; Tsubakihara Y;
    Ther Apher Dial; 2013 Apr; 17(2):221-8. PubMed ID: 23551679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to mineral and bone disorder clinical practice guidelines in chronic kidney disease.
    Panawong W; Chaiyakum A; Pongskul C
    J Med Assoc Thai; 2011 Oct; 94(10):1175-83. PubMed ID: 22145501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compliance with mineral metabolism targets in haemodialysis patients: moving backwards?
    Palomares I; Ramos R; Martin-Malo A; Merello JI; Praga M; Luño J; de Francisco AL;
    Blood Purif; 2013; 36(2):122-31. PubMed ID: 24217176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
    Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
    Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Kimata N; Akiba T; Pisoni RL; Albert JM; Satayathum S; Cruz JM; Akizawa T; Andreucci VE; Young EW; Port FK
    Nephrol Dial Transplant; 2005 May; 20(5):927-35. PubMed ID: 15728270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between Hemodialysis Patient Outcomes and Compliance with KDOQI and KDIGO Targets for Mineral and Bone Metabolism.
    Djukanović L; Dimković N; Marinković J; Djurić Ž; Knežević V; Lazarević T; Ljubenović S; Marković R; Rabrenović V
    Nephron; 2016; 132(3):168-74. PubMed ID: 26914677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study.
    Naves-Díaz M; Passlick-Deetjen J; Guinsburg A; Marelli C; Fernández-Martín JL; Rodríguez-Puyol D; Cannata-Andía JB
    Nephrol Dial Transplant; 2011 Jun; 26(6):1938-47. PubMed ID: 20513773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry.
    Tangri N; Wagner M; Griffith JL; Miskulin DC; Hodsman A; Ansell D; Naimark DM
    Am J Kidney Dis; 2011 Mar; 57(3):415-21. PubMed ID: 21131115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study.
    Fernández-Martín JL; Martínez-Camblor P; Dionisi MP; Floege J; Ketteler M; London G; Locatelli F; Gorriz JL; Rutkowski B; Ferreira A; Bos WJ; Covic A; Rodríguez-García M; Sánchez JE; Rodríguez-Puyol D; Cannata-Andia JB;
    Nephrol Dial Transplant; 2015 Sep; 30(9):1542-51. PubMed ID: 25920921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CA-P control in haemodialysis and K/DOQI guidelines].
    Rivera F; Sánchez de la Nieta MD; Echarri R; Anaya S; Carreño A; Vozmediano MC; Alcaide MP
    Nefrologia; 2006; 26(3):351-7. PubMed ID: 16892824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort.
    Lamina C; Kronenberg F; Stenvinkel P; Froissart M; Forer L; Schönherr S; Wheeler DC; Eckardt KU; Floege J
    Nephrol Dial Transplant; 2020 Mar; 35(3):478-487. PubMed ID: 31006013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to K/DOQI guidelines for calcium-based phosphate binders in clinical practice.
    Shastri J; Tran A; Covit A; Pepe J; Sherman RA
    J Ren Nutr; 2008 Jul; 18(4):370-4. PubMed ID: 18558302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey.
    Cozzolino M; Brancaccio D; Cannella G; Messa P; Gesualdo L; Marangella M; LoDeserto C; Pozzato M; Rombolà G; Costanzo AM; di Luzio Paparatti U; Mazzaferro S;
    Nephrol Dial Transplant; 2012 Sep; 27(9):3588-94. PubMed ID: 22523119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
    Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E
    Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study.
    Lorenzo V; Martin-Malo A; Perez-Garcia R; Torregrosa JV; Vega N; de Francisco AL; Cases A
    Nephrol Dial Transplant; 2006 Feb; 21(2):459-65. PubMed ID: 16263739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological impact of targeted dialysate calcium changes in haemodialysis patients: the key role of parathyroid hormone.
    Jean G; Mayor B; Hurot JM; Deleaval P; Lorriaux C; Zaoui E; Chazot C
    Nephrol Dial Transplant; 2013 Jan; 28(1):176-82. PubMed ID: 22764192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.